Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235484 | 0.81 | ESR1 (0.46) | HPGDRAB9ASMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL5915148 | 0.81 | RAB9A (0.59) | HPGDRAB9ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL13237374 | 0.78 | NPC1 (0.54) | HPGDRAB9ASMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL19224717 | 0.75 | NPC1 (0.51) | HPGDRAB9ASMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL31379292 | 0.74 | FFAR1 (0.39) | RAB9AL3MBTL1NPC1POLBNPSR1 | |
| SCHEMBL31379407 | 0.71 | KDM1A (0.38) | HPGDRAB9ASMN1; SMN2TP53L3MBTL1 | |
| Hydrazinecarboxamide SCHEMBL22471911 | 0.68 | RAB9A (0.45) | HPGDRAB9ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL17994177 | 0.68 | NOTUM (0.48) | HPGDRAB9ASMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL16561361 | 0.67 | IDO1 (0.58) | TSHRMAOBLOXL2 | |
| SCHEMBL1468357 | 0.67 | IDO1 (0.58) | TSHRMAOBLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391611-B1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2391611-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
| EP-1644377-A4 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | SUGEN INC (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7122548-B2 | Triazolotriazine compounds and uses thereof | SUGEN, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-7037909-B2 | Tetracyclic compounds as c-Met inhibitors | SUGEN, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1644377-A1 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | SUGEN, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005010005-A1 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | SUGEN, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005004808-A2 | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050014755-A1 | Tetracyclic compounds as c-Met inhibitors | SUGEN INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014755-A1 | Tetracyclic compounds as c-Met inhibitors | MET, RET, HGF | HPGD 4576/4885RAB9A 921/4885SMN1; SMN2 3903/4885 |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | HPGD 28/4885RAB9A 3120/4885SMN1; SMN2 2115/4885 |
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | MET, TPMT, RET | HPGD 3276/4885RAB9A 3884/4885SMN1; SMN2 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.